Multitude Therapeutics
- Biotech or pharma, therapeutic R&D
Multitude Therapeutics is a clinical-stage company focused on the development of ADC drugs. Multitude Therapeutics has two technology platforms: MabArray— an antibody platform for discovering novel cell surface tumor targets to construct first-in-class targets, and T moiety exatecan — a new linker-payload technology for developing ADCs, which allows ADCs prepared with this platform to achieve a better balance of the bystander effect, efficacy, and safety. The combination of MabArray and T moiety exatecan generates significant synergistic effects, enabling Multitude Therapeutics to build an ADC "atlas"that is expected to treat malignant tumors with high unmet medical needs and achieve higher and more durable responses.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}